High-potency topical corticosteroids applied directly to the skin are the best first-line treatment for bullous pemphigoid, outperforming oral steroids in both disease control and survival. A landmark study published in the New England Journal of Medicine found that topical steroids controlled the disease in 99% of patients with extensive blistering within three weeks, compared to 91% for oral steroids. More importantly, one-year survival was 76% with topical treatment versus 58% with oral steroids, largely because topical treatment causes far fewer dangerous side effects.
Why Topical Steroids Beat Oral Steroids
Bullous pemphigoid primarily affects older adults, many of whom already have conditions like diabetes, osteoporosis, or heart disease. Oral steroids worsen all of these. In the NEJM trial comparing the two approaches, severe complications occurred in 54% of patients taking oral steroids but only 29% of those using topical treatment. Among patients with extensive disease, deaths were nearly twice as high in the oral steroid group (41%) compared to the topical group (24%).
For moderate cases with fewer blisters, both approaches performed similarly in terms of survival and complication rates. But because topical steroids work at least as well across the board and carry less risk, they’ve become the preferred starting point regardless of severity. The typical regimen involves applying a high-potency cream to the entire body (not just the blisters) once or twice daily.
What the Treatment Timeline Looks Like
Most patients see their blisters come under control within the first three weeks of treatment. Between 69% and 75% of patients on oral steroids achieve disease control by week three, and topical steroids work even faster for many people. Once the blistering stops, the goal shifts to gradually reducing treatment while watching for flare-ups.
Current guidelines recommend starting to taper steroid therapy two to three weeks after achieving disease control. For oral steroids, the dose is gradually reduced over four to six months. After reaching a minimal dose, treatment may continue for another three to six months before stopping entirely. Topical regimens follow a similar slow taper, reducing the frequency of application over several months. Stopping too quickly is one of the main triggers for relapse.
Even with careful tapering, relapse is common. A multicenter study tracking patients after they stopped treatment found that 53% experienced at least one relapse within the first year. This is why treatment plans often extend well beyond the point where blisters have cleared, and why many patients need additional medications to keep the disease in check long-term.
Steroid-Sparing Medications
Because long-term steroid use raises the risk of bone loss, high blood sugar, weight gain, and infections, doctors often add a second medication that allows the steroid dose to come down sooner. The most commonly used options are azathioprine and mycophenolate mofetil, both of which suppress the overactive immune response driving the blistering.
Before starting azathioprine, a blood test checks for an enzyme that affects how your body processes the drug. People with normal enzyme levels can tolerate standard doses, while those with lower levels need a reduced amount to avoid serious side effects like dangerously low blood cell counts. Mycophenolate mofetil is dosed by body weight, typically around 2 grams daily for an average-sized adult. Both medications take several weeks to reach full effect, so steroids remain necessary during the transition period.
Antibiotic Combinations for Milder Cases
For people with limited blistering or those who can’t tolerate steroids due to other health problems, a combination of doxycycline (an antibiotic with anti-inflammatory properties) and nicotinamide (a form of vitamin B3) offers a gentler alternative. In a clinical trial of 11 patients with less extensive disease, six achieved more than 90% clearance of their blisters, and two more saw 50% to 90% improvement.
This combination works through mild anti-inflammatory effects rather than broad immune suppression, which makes it significantly safer for elderly patients with diabetes, heart failure, or other conditions that steroids would aggravate. The response tends to be slower and less reliable than with steroids, so this approach is best suited for localized disease rather than widespread blistering.
Biologic Therapies for Resistant Cases
When standard treatments fail or the disease keeps relapsing, newer biologic medications offer a meaningful alternative. A systematic review of 211 patients treated with three different biologics found encouraging results across the board.
- Rituximab achieved complete remission in 70.5% of patients within about six months, though 20.5% later relapsed. It works by depleting a specific type of immune cell responsible for producing the antibodies that attack the skin.
- Omalizumab led to complete remission in 67.9% of patients within roughly seven months, with only a 5.7% recurrence rate.
- Dupilumab produced complete remission in 66.7% of patients in about four and a half months, with the lowest recurrence rate at 5.6% and no reported adverse events in the review.
While all three biologics showed similar overall effectiveness, dupilumab stands out for its favorable safety profile and the fact that patients can inject it at home. These treatments are typically reserved for cases that haven’t responded to at least two conventional therapies, and access may depend on insurance coverage and specialist availability.
Monitoring During Long-Term Treatment
Bullous pemphigoid treatment often lasts a year or longer, and any medication that suppresses the immune system or involves steroids requires regular monitoring. Before starting treatment, your doctor will typically check your blood counts, blood sugar, cholesterol levels, blood pressure, weight, and bone density. These serve as a baseline for catching problems early.
Blood sugar is especially important to watch because steroids can push glucose levels into the diabetic range even in people who were previously healthy. Glucose should be monitored closely for the first 48 hours after starting steroids, then every three to six months during the first year, and annually after that. Cholesterol and cardiovascular risk factors are checked about a month after treatment begins and then every six to twelve months. For patients on azathioprine or mycophenolate, regular blood counts are necessary to catch drops in white blood cells that could increase infection risk.
Bone density screening matters because prolonged steroid use accelerates bone loss. Many patients are started on calcium and vitamin D supplements as a preventive measure, and some may need additional bone-protective medication depending on their baseline density and other risk factors.